By Anthony O. Goriainoff

AstraZeneca PLC said Monday that Imfinzi had been approved by the U.S. Food and Drug Administration for the treatment of adult patients with advanced biliary tract cancer in combination with chemotherapy.

The London-listed pharmaceutical company said that an interim analysis from the TOPAZ-1 Phase 3 trial showed Imfinzi plus chemotherapy reduced the risk of death by 20% versus chemotherapy alone.

The Anglo-Swedish pharma giant said Imfinzi was under regulatory review in Europe, Japan, Brazil, Australia, Canada and Israel, among other regions.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

September 05, 2022 02:34 ET (06:34 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more AstraZeneca Charts.